Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Free Report) insider David Krempa sold 4,166 shares of the business’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $55.07, for a total transaction of $229,421.62. Following the completion of the sale, the insider directly owned 43,381 shares of the company’s stock, valued at $2,388,991.67. This represents a 8.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
David Krempa also recently made the following trade(s):
- On Monday, August 24th, David Krempa sold 25,000 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $65.07, for a total transaction of $1,626,750.00.
Eton Pharmaceuticals Trading Down 1.5%
Shares of NASDAQ:ETON traded down $0.85 on Tuesday, reaching $54.77. 467,654 shares of the company traded hands, compared to its average volume of 447,832. The business’s 50-day simple moving average is $55.19 and its 200 day simple moving average is $39.32. Eton Pharmaceuticals, Inc. has a 52 week low of $14.27 and a 52 week high of $66.37. The stock has a market capitalization of $1.57 billion, a P/E ratio of 144.13 and a beta of 0.90. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.41.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the business. Toth Financial Advisory Corp bought a new stake in Eton Pharmaceuticals during the second quarter worth about $43,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Eton Pharmaceuticals during the fourth quarter valued at approximately $50,000. Persistent Asset Partners Ltd bought a new position in shares of Eton Pharmaceuticals during the second quarter valued at approximately $90,000. State of Wyoming purchased a new position in shares of Eton Pharmaceuticals during the second quarter valued at approximately $107,000. Finally, Quantbot Technologies LP purchased a new position in shares of Eton Pharmaceuticals during the second quarter valued at approximately $165,000. 27.86% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of research firms have recently weighed in on ETON. Canaccord Genuity Group increased their price objective on Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a research note on Friday, August 14th. Craig Hallum raised their target price on Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. HC Wainwright upped their price target on Eton Pharmaceuticals from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, August 14th. B. Riley Financial reiterated a “buy” rating and issued a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a research report on Friday, August 14th. Finally, Wall Street Zen upgraded Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $67.50.
Read Our Latest Research Report on ETON
Eton Pharmaceuticals Company Profile
Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases and other underserved patient populations. The company’s strategy includes advancing proprietary product candidates and obtaining rights to established medicines that can address unmet medical needs.
Eton’s portfolio has included products such as Eprontia (topiramate) oral solution for certain seizure disorders and migraine prevention, Biorphen (phenylephrine hydrochloride) injection for the treatment of clinically important hypotension, and specialty medicines used in the management of rare metabolic and endocrine conditions.
Featured Stories
- Five stocks we like better than Eton Pharmaceuticals
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
- Lamb Weston’s Turnaround Is Starting to Look Real
- These 3 Stocks Got the Most Love From Analysts in September
- Record French Debt Could Create Opportunities for U.S. Market Operators
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
